Compare Danaher Corporation (DHR) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Lemonade Inc — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Lemonade Inc trades at $46.46 (market cap $3.63B). The key difference: Danaher Corporation is far larger — about 42.1× Lemonade Inc's market cap, and Danaher Corporation pays a 0.74% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Lemonade Inc for 27 Days on average.
| DHR | LMND | |
|---|---|---|
Market Cap | $152.87B | $3.63B |
Volume | 5,228,698 | 1,544,794 |
Sector | Health | Financials |
52-Week High | $242.05 | $96.57 |
52-Week Low | $161.91 | $43.91 |
Typical Hold Time | 69 Days | 27 Days |
Enterprise Value | $175.08B | $3.49B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
Lemonade (LMND) trades at $46.91, showing modest daily gains of 0.17%. The stock faces bearish technical signals despite recent earnings beats, with revenue growth accelerating to 32% year-over-year in Q2 2026. The company demonstrates improving fundamentals with gross profit margin at 47.85% and narrowing losses, targeting EBITDA profitability by late 2026. Recent expansion into Alaska and Kentucky markets supports growth trajectory.
Lemonade presents a growth story with improving margins and AI-driven efficiency, but profitability remains elusive. The 33% upside to consensus price target of $67 offers potential reward, though persistent losses and competitive pressures pose significant risks. Investors must weigh the company's expansion momentum against its negative cash flow from operations and high valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
